Global Blood Screening Market 2025-2035

Blood Screening Market Size, Share & Trends Analysis Report by Product Type (Reagents & Kits, Instruments, and Software & Services) by Technology (Enzyme and Chemiluminescent immunoassays (EIA/CLIA), Nucleic Acid Amplification Testing (NAT), Chemiluminescence Immunoassay (CLIA), Western Blotting, and Next-Generation Sequencing (NGS)) and by End User (Blood Banks, and Hospitals & Diagnostic Laboratories) Forecast Period (2026-2035)

Industry Overview

Blood screening market was valued at $3.7 billion in 2025 and is projected to reach $10.9 billion by 2035, growing at a CAGR of 11.3% during the forecast period (2026-2035). The growing need for safe transfusions globally has made efficient and high-volume blood screening solutions increasingly essential. Increasing volumes of donations combined with the varied transfusion needs from across the globe further underscore the central role that screening technologies play in ensuring a safe blood supply, in addition to avoiding the risk of transfusion-transmissible diseases. For instance, in May 2025, the World Health Organization (WHO) reported that-

• 40% of the 118.5 million blood donations globally are collected in high-income countries, which comprise 16% of the global population.
• Low-income nations provide 54% of transfusions for children aged under 5 years, whereas high-income nations provide 76% of all transfusions for people aged over 60 years.
• The donation rate per blood donation differed across various income levels, with the highest donation rate being at 31.5 donations in high-income countries, followed by 16.4 in upper-middle-income countries, 6.6 in lower-middle-income countries, and 5.0 in low-income countries.
• Plasma volume fractionation per 1000 population in 45 countries differed considerably, with the median being 5.2 litres.

Market Dynamics

Growth Driven by Higher Burden of Infectious Diseases

Global blood screening market is growing at a faster rate with the increased burden of infectious as well as chronic diseases that require early and precise detection of biomarkers. Growing awareness among patients and healthcare providers, along with improvements in diagnostic technology, is driving the use of advanced blood tests in hospitals, laboratories, and research institutions. Additionally, regulatory clearances and the establishment of high-throughput, automated platforms are facilitating quicker, more accurate screening, thus increasing market penetration globally.

The growing incidence of infectious diseases such as HIV, hepatitis B, hepatitis C, and syphilis is fueling the adoption of sophisticated screening technologies and market expansion. For instance, in April 2025, Quest Diagnostics launched the AD-Detect Blood Test, which helps to validate amyloid brain disease characteristic of Alzheimer's disease in patients with mild cognitive impairment or dementia. The in-house test, AD-Detect Abeta 42/40 and p-tau217 Evaluation, quantifies amyloid beta (AB) 42/40 by using proprietary tandem mass spectrometry and quantifies p-tau217 using an in vitro immunoassay. The findings produce the AD-Detect Likelihood Score, from a validated algorithm developed at the 1Florida Alzheimer's Disease Research Center. The test panel is an improvement on earlier AD-Detect tests that measured AB 42/40, p-tau217, p-tau181, and the ApoE isoform, targeting the risk of Alzheimer's instead of diagnosing amyloid pathology.

Market Segmentation

• Based on the product type, the market is segmented into reagents & kits, instruments, and software & services.
• Based on the technology, the market is segmented into enzyme and chemiluminescent immunoassays (EIA/CLIA), nucleic acid amplification testing (NAT), chemiluminescence immunoassay (CLIA), western blotting, and next-generation sequencing (NGS).
• Based on the end user, the market is segmented into blood banks, hospitals & diagnostic laboratories.

Blood Banks: A Key Segment in Market Growth

The increasing volume of global blood donations is fueling demand for accurate screening technologies to provide safe transfusions and supporting market growth. As per the World Health Organization (WHO), in May 2025, it was reported that a total of 106 million blood donations were received by about 13,300 blood centers in 169 countries. The volume of donations received in these blood centers varies according to the income status of the country. In poor countries, the median donations per year per center are 1,300, and in lower-middle-income and upper-middle-income countries, respectively, it is 4,400 and 9,300. The high-income nations have a much larger median of 25,700 donations per center per year.

Regional Outlook

The global blood screening market is further divided by region, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Technological Advances Leading the Growth in the Asia-Pacific Blood Screening Market

The growth of medical diagnostics is being driven by advances in automation, molecular test platforms, and non-invasive diagnostic technology. For instance, in May 2025, Hyderabad developed India's first needle-free, Artificial Intelligence (AI)-driven blood test utilizing Photoplethysmography (PPG) technology. This non-invasive process evaluates major health parameters, including blood pressure, oxygen saturation, heart rate, respiration rate, hemoglobin A1c, stress levels, and pulse respiratory quotient.

North America Maintains Strong Market Position

North America holds a significant share, owing to the market growth is primarily driven by the US government policies and healthcare programs in North America are becoming more centered on enhancing preventive healthcare, early disease detection, and accessibility of high-risk groups, especially the elderly. All these are contributing positively to the global blood screening market through the improvement of reimbursement mechanisms, facilitation of the uptake of new-generation diagnostic tests, and a boost in regular health monitoring. Supportive policies, regulatory clearances, and insurance coverage are encouraging healthcare providers and patients to undergo blood-based screening tests, which tend to be more convenient and less invasive than the conventional diagnostic tests. The US FDA cleared the first liquid biopsy, a blood test called Shield, as a colorectal cancer screen. For instance, in July 2024, the US FDA approved the first liquid biopsy, a blood test named Shield, for colorectal cancer screening. Set to be available commercially within the next week, Shield is the first blood test to be approved by the FDA as a primary screening option for colorectal cancer that also qualifies for Medicare reimbursement. While the test's convenience may increase screening participation, experts emphasize that blood tests do not prevent colorectal cancer and are not a substitute for colonoscopy. Recent studies in Gastroenterology and Clinical Gastroenterology, and Hepatology highlight the limitations of liquid biopsy.

Market Players Outlook

The major companies operating in the global blood screening market include Abbott Laboratories, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Grifols S.A., Thermo Fisher Scientific Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to drive business expansion and innovative product development, thereby maintaining their market positioning.

Recent Developments

• In June 2025, Devyser introduced Devyser Genomic Blood Typing, a next-generation sequencing-based test simplifying molecular blood group investigation. The one-test solution addresses red blood cell, human platelet antigen, and human neutrophil antigen systems in a single assay. It overcomes the complexities of blood group analysis in transfusion and transplantation investigation with high-resolution output and software-assisted interpretation for workflow ease.
• In December 2024, BD and Babson Diagnostics brought fingertip blood testing to healthcare organizations. The solution integrates BD's MiniDraw Capillary Blood Collection System with Babson's BetterWay technologies to provide laboratory results from as few as six drops of capillary blood collected from a patient's finger. The minimally invasive alternative allows trained healthcare workers to draw and prepare samples without having to first acquire phlebotomy skills.
• In December 2024, Strand Life Sciences introduced CancerSpot, a blood test for the early detection of cancer. It utilizes sophisticated methylation profiling technology to detect tumor DNA pieces in the blood, providing a non-invasive and cost-effective screening solution. Developed based on Indian populations, it can be applied anywhere in the globe.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global blood screening market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.

Show more